ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1463

Pulmonary Hypertension and Interstitial Lung Disease within Pharos:  Impact of Extent of Fibrosis and Pulmonary Physiology On Cardiac Hemodynamic Parameters

Aryeh Fischer1, Stephen C. Mathai2, Marcy B. Bolster3, Lorinda Chung4, Mary Ellen Csuka5, Robyn T. Domsic6, Tracy M. Frech7, Monique E. Hinchcliff8, Vivien M. Hsu9, Laura K. Hummers10, Jason R. Kolfenbach11, Mardi Gomberg-Maitland12, Aida Manu13, Robert W. Simms14 and Virginia D. Steen15, 1Rheumatology / ILD Program, National Jewish Health, Denver, CO, 2Medicine, Johns Hopkins University, Baltimore, MD, 3Medicine, Medical Univ of South Carolina, Charleston, SC, 4Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, 5Rheumatology, Medical College of Wisconsin, Milwaukee, WI, 6Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, 8Division of Rheumatology, Northwestern Univ Med School, Chicago, IL, 9Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 10Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 11Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 12University of Chicago, Chicago, 13Rheumatology, Georgetown University Medical Center, Disrict of Columbia, 14Rheumatology, Boston University School of Medicine, Boston, MA, 15Department of Rheumatology, Georgetown University Medical Center, Washington, DC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of mortality in systemic sclerosis (SSc).  Many SSc patients have both pulmonary hypertension (PH) and ILD and it can be difficult to distinguish PAH from PH secondary to chronic ILD (PH-ILD).  In addition, it is not known to what degree the extent of ILD or pulmonary physiology impact cardiac hemodynamic parameters of PAH. The purpose of this study was to determine the impact that extent of ILD and degree of pulmonary physiologic restriction have on specific cardiac hemodynamic parameters within a subset of the PHAROS cohort. 

Methods: We identified PHAROS subjects with right-heart catheter-proven PH that had a forced vital capacity (FVC) < 70% predicted or that had ILD reported on computed tomography (CT) scans. Subjects with pulmonary venous hypertension (wedge pressure >15mmHg) were excluded.  Baseline CT scans were scored by the investigator at each site by a standardized system that graded severity of ILD as none (0), mild (1), moderate (2), or severe (3) at 5 specific zones distributed throughout the lungs.  A cumulative score based on summation of the score for all 5 zones was generated from each CT scan and defined as none-mild (sum=0-5), moderate (sum=6-10), or severe (sum=11-15). 

Results: Sixty subjects met the inclusion criteria and had CT scoring performed:  19 had none-mild, 26 had moderate, and 15 had severe ILD.  There were no differences between groups with respect to age (mean 57+/-11) or SSc type (43% diffuse).  None-mild ILD was associated with higher mean pulmonary artery pressures (mPAP) (41.8+/-10.7) than moderate (32.7+/-8.4;p=0.002) and severe ILD (mPAP 34.3+/-8.1;p=0.03) or the combination of moderate and severe ILD (33.3+/-8.2;p=0.001).  None-mild ILD was also associated with higher pulmonary vascular resistance (PVR) (623+/-340) than seen with combined moderate and severe ILD (361+/-227;p=0.001).  There were no differences in mPAP or PVR between moderate and severe ILD or between the combinations of none-mild-moderate ILD compared with severe ILD.  In contrast, when stratified by FVC, no differences in mean PAP or PVR were identified.  FVC was not a reliable predictor of the extent of ILD in this cohort:  29% of those with FVC% less than 70 had none-mild ILD, and in those with FVC% greater than 70, 54% had moderate and 16% had severe ILD. 

Conclusion: Within this PHAROS subset, significant differences in cardiac hemodynamics were associated with varied extent of ILD but not with degree of restriction estimated by FVC.  Furthermore, FVC alone was not a reliable predictor of degree of ILD.   Further studies, incorporating CT extent of ILD along with pulmonary physiology, are needed to help determine ways to distinguish PAH from PH-ILD.


Disclosure:

A. Fischer,

Actelion Pharmaceuticals US,

8,

Gilead Pharmaceuticals,

8,

Actelion Pharmaceuticals US,

5,

Gilead Pharmaceuticals,

5,

Gilead Pharmaceuticals,

2;

S. C. Mathai,
None;

M. B. Bolster,
None;

L. Chung,

Gilead and Actelion,

5,

Gilead, Actelion, Pfizer, United Therapeutics,

2;

M. E. Csuka,
None;

R. T. Domsic,
None;

T. M. Frech,
None;

M. E. Hinchcliff,
None;

V. M. Hsu,
None;

L. K. Hummers,
None;

J. R. Kolfenbach,
None;

M. Gomberg-Maitland,
None;

A. Manu,
None;

R. W. Simms,
None;

V. D. Steen,

Gilead,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-hypertension-and-interstitial-lung-disease-within-pharos-impact-of-extent-of-fibrosis-and-pulmonary-physiology-on-cardiac-hemodynamic-parameters/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology